fashion -WSS

fashion

author：leisure time 2025-10-01 12:11:54 - browse：8

Sarepta - Cambridge -AP — A logo sign outside of the headquarters of Sarepta Therapeutics in Cambridge, Mass. Kristoffer Tripplaar/Sipa via AP

Reviewers at the Food and Drug Administration were leaning toward rejecting a closely watched gene therapy for Duchenne muscular dystrophy made by Sarepta Therapeutics, prompting a top official to intervene earlier this year, according to three people with direct knowledge of the agency deliberations.

Inside the FDA office that oversees gene therapies, some staff had reached a non-binding conclusion that Sarepta’s gene therapy should be rejected, the individuals said, speaking on condition of anonymity. Peter Marks, a top FDA official and vocal advocate for faster gene therapy approvals, stepped in and directed staff to schedule a public hearing on the therapy on May 12.

Sarepta announced the scheduling of the public hearing last month, but the internal deliberations that led to it have not been previously reported.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Cancer drug shortages should be causing more outrage
Next article： Why Charlie Gard's case is so disturbing to Americans

hotspot

leisure time

WSS

Physician executives need more than on

Physician subsidies by hospitals soar in wake of No Surprises Act

Biden's order seeks to regulate AI risk without stifling innovation

WHO may add ‘noma' to its list of neglected tropical diseases

Readout Newsletter: New research from Sanofi, Regeneron, etc.

Bill would stop addiction treatment from triggering child abuse inquiry

focus

fashion

focus

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Hospitals warn Medicare's drug payment fix is ‘unlawful’

Psychedelics group wrestles with new pharma identity

First Opinion Podcast: How to protect health care in times of war

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

CDC recommends rationing of RSV shot due to shortages

The cancer drug shortage isn’t new — and neither are the solutions

Hospitals warn Medicare's drug payment fix is ‘unlawful’

Novavax promises a turnaround & Lilly roils the obesity market

Testing for cancer recurrence creates a new limbo for patients

knowledge

STAT Wunderkinds: Ruey Hu's digital tools for parsing research

Histogen: Failed biotech offers rare public look inside

FDA panel signals lack of confidence in Amgen cancer drug data

Traditional Chinese medicine benefits explored in new JAMA study

First Opinion Podcast: How to protect health care in times of war

A Q&A with the global head of Boehringer Ingelheim's innovation unit

entertainment

hotspot

leisure time

leisure time